Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.8 USD | +8.63% | +1.68% | -63.11% |
Apr. 30 | Medifast Shares Drop as Q1 Adjusted Earnings, Revenue Decline; Sets Q2 Guidance | MT |
Apr. 30 | Wall Street Poised for Cautious Day Ahead of Key Numbers, Earnings, Fed Report | MT |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.13 for the 2024 fiscal year.
- The company has a low valuation given the cash flows generated by its activity.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-63.11% | 265M | C- | ||
+13.74% | 8.18B | D+ | ||
+5.29% | 7.53B | C- | ||
-0.42% | 5.89B | - | ||
-6.67% | 3.7B | B- | ||
-10.75% | 3.57B | D | ||
-8.21% | 1.26B | - | - | |
-29.10% | 1.08B | B+ | ||
+14.92% | 991M | - | ||
-12.46% | 894M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MED Stock
- Ratings Medifast, Inc.